var data={"title":"Tobramycin (oral inhalation): Pediatric drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tobramycin (oral inhalation): Pediatric drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/788627?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tobramycin-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Tobramycin (oral inhalation): Drug information \t&quot;</a> and <a href=\"topic.htm?path=tobramycin-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tobramycin (oral inhalation): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031230\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bethkis;</li>\n      <li>Kitabis Pak;</li>\n      <li>Tobi;</li>\n      <li>Tobi Podhaler;</li>\n      <li>Tobramycin Pak [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031231\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>TOBI;</li>\n      <li>TOBI Podhaler</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503733\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Aminoglycoside</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503737\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tobramycin-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Tobramycin (oral inhalation): Drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulmonary infection:</b> Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cystic fibrosis (CF) patients: Children &ge;6 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Bethkis, Kitabis Pak, TOBI: 300 mg every 12 hours; administer in repeated cycles of 28 days on drug, followed by 28 days off drug</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">TOBI Podhaler: 112 mg (4 x 28 mg capsules) every 12 hours; administer in repeated cycles of 28 days on drug followed by 28 days off drug</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Noncystic fibrosis patients: Limited data available: <b>Note:</b> Doses are from initial studies of CF patients using the IV product as inhalation (MacLusky 1989; Steinkamp 1989). Some centers utilize this dose in non-CF patients for treatment of pulmonary disease (eg, bronchiectasis, tracheitis) (Rubin 2008): Children and Adolescents: 80 mg/dose 2 to 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis:</b> Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bethkis, Kitabis Pak, TOBI: 300 mg every 12 hours (do not administer doses &lt;6 hours apart); administer in repeated cycles of 28 days on drug followed by 28 days off drug</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">TOBI podhaler: 112 mg (4 x 28 mg capsules) every 12 hours (do not administer doses &lt;6 hours apart); administer in repeated cycles of 28 days on drug followed by 28 days off drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Inhalation: Children &ge;6 years, Adolescents, and Adults: No dosage adjustment necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031304\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tobi Podhaler: 28 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tobramycin Pak: 300 mg/5 mL (5 mL [DSC]) [contains sodium chloride, sodium hydroxide, sulfuric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization Solution, Inhalation [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bethkis: 300 mg/4 mL (4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kitabis Pak: 300 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tobi: 300 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/5 mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031233\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503738\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Inhalation: Doses should be administered as close to a 12-hour schedule  as possible; do not administer less than 6 hours apart</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bethkis, Kitabis Pak, TOBI: Use a PARI LC Plus reusable nebulizer and a PARI Vios air compressor (Bethkis) or a DeVilbiss Pulmo-Aide air compressor (Kitabis Pak, TOBI) for administration; patient should be sitting or standing upright and breathing normally through the mouthpiece of the nebulizer. Nebulizer treatment period is usually over 15 minutes. If patient receiving multiple inhalation products, administer bronchodilator first, followed by chest physiotherapy, any other nebulized medications, and then tobramycin last. Do not mix with other nebulizer medications. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TOBI  Podhaler: Capsules should be administered by oral inhalation via Podhaler device following manufacturer recommendations  for use and handling. Capsules should  be removed from the blister packaging immediately prior to use and should not be swallowed. Patients requiring bronchodilator therapy should administer the bronchodilator 15 to 90 minutes prior to TOBI Podhaler. The sequence of chest physiotherapy and additional inhaled therapies is at the discretion of the healthcare provider; however, TOBI Podhaler should always be administered last. Use  the new podhaler device provided with each weekly pack.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031263\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder, for inhalation (Tobi Podhaler):  Store in original package at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, for inhalation (Bethkis, Kitabis Pak, Tobi): Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). May be stored in foil pouch (opened or unopened) at room temperature of 25&deg;C (77&deg;F) for up to 28 days. Protect from light. The colorless to pale yellow solution may darken over time if not stored under refrigeration; however, the color change does not affect product quality. Do not use if solution has been stored at room temperature for &gt;28 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503734\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of cystic fibrosis patients with <i>P. aeruginosa</i> (FDA approved in ages &ge;6 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031224\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tobramycin may be confused with Trobicin, vancomycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031253\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest discomfort</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache, malaise, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine: Increased serum glucose (more common with powder)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, dysgeusia (more common with powder), nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia (solution), increased erythrocyte sedimentation rate (solution), increased serum immunoglobulins (solution)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Musculoskeletal chest pain, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Deafness (including unilateral deafness, reported as mild to moderate hearing loss or increased hearing loss), hypoacusis (powder), tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: bronchitis (solution), bronchospasm, cough (more common with powder), decreased lung function, discoloration of sputum, dyspnea, epistaxis, hemoptysis, laryngitis (solution), nasal congestion, oropharyngeal pain, pharyngolaryngeal pain (more common with powder), productive cough, pulmonary disease (includes pulmonary or cystic fibrosis exacerbations), rales (more common with solution), reduced forced expiratory volume (more common with solution), rhinitis (solution), throat irritation, tonsillitis (solution), upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Aphonia, decreased appetite, hypersensitivity reaction, increased bronchial secretions, pneumonitis, pruritus, pulmonary congestion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031248\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tobramycin, other aminoglycosides, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031249\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bronchospasm: Bronchospasm may occur; bronchospasm or wheezing should be treated appropriately if either arise. Safety and efficacy have not been demonstrated in patients with FEV<sub>1</sub> &lt;40% or &gt;80% predicted (Bethkis, TOBI) or FEV<sub>1</sub> &lt;25% or &gt;80% predicted (TOBI Podhaler) or FEV<sub>1</sub> &lt;25% or &gt;75% predicted (Kitabis Pak), in patients colonized with <i>Burkholderia cepacia</i>, or in patients &lt;6 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity: Nephrotoxicity was not observed during tobramycin inhalation clinical studies, but has been associated with aminoglycosides. If nephrotoxicity occurs, discontinue therapy until serum concentrations fall below 2 mcg/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis and Parkinson disease; neuromuscular blockade, respiratory failure, and prolonged respiratory paralysis may occur due to aminoglycoside-related curare-like effect on neuromuscular function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: Ototoxicity, as measured by complaints of hearing loss or tinnitus, has been reported. Tinnitus may be a sentinel symptom of ototoxicity, and therefore, the onset of this symptom warrants further investigation. Ototoxicity, manifested as both auditory and vestibular toxicity, has been reported with parenteral aminoglycosides. Vestibular toxicity may be manifested by vertigo, ataxia, or dizziness. Patients with known or suspected auditory or vestibular dysfunction should be closely monitored (audiometric evaluations and serum tobramycin concentrations). Consider monitoring serum tobramycin concentrations if neurotoxicity is suspected or with concurrent use of parenteral aminoglycosides. If neurotoxicity occurs, discontinue therapy until serum concentrations fall below 2 mcg/mL. Baseline audiogram should be considered for patients at increased risk of auditory dysfunction. Use with caution in patients with preexisting vertigo, tinnitus, or hearing loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45504057\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">With use of Tobi podhaler (oral capsule powder for inhalation), taste disturbance (dysgeusia) was reported more frequently in pediatric patients &ge;6 years (7.4%) than adults (2.7%). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031258\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031255\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105136&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the nephrotoxic effect of Tobramycin (Oral Inhalation). Loop Diuretics may enhance the ototoxic effect of Tobramycin (Oral Inhalation).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Tobramycin (Oral Inhalation).<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031244\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031245\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Aminoglycosides may cause fetal harm if administered to a pregnant woman. Tobramycin crosses the placenta when given by injection. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Tobramycin inhalation may be used for the management of cystic fibrosis in pregnant patients with <i>Pseudomonas aeruginosa</i> (Edenborough 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503739\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">The utility of monitoring serum concentrations in patients with renal impairment should be per clinician's discretion; serum concentrations achieved following inhalation are significantly less than those achieved following parenteral therapy in patients with normal renal function. Monitor serum tobramycin concentrations in patients with known or history of auditory dysfunction, renal dysfunction, and/or concomitant use of nephrotoxic drugs. One hour after inhalation, serum concentrations of 1 to 2 mcg/mL have been observed. Obtaining peak tobramycin concentration 1 hour following inhalation to identify patients who are significant absorbers, in patients with decreased glomerular filtration rate, in patients on concomitant parenteral therapy, and in infants have been recommended by some clinicians (Abdulhamid 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503740\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Inhalation: Serum concentrations are ~1 to 2 mcg/mL 1 hour following a dose in patients with normal renal function. Routine monitoring of serum concentrations is not required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031267\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit, resulting in a defective bacterial cell membrane</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031270\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Inhalation: Peak serum concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solution for inhalation: ~1 mcg/mL following a 300 mg dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Powder for inhalation: ~1 mcg/mL (range: 0.49 to 1.55 mcg/mL) following a 112 mg dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Powder for inhalation:  V<sub>d</sub> (central compartment) for a typical cystic fibrosis patient: 85.1 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solution for inhalation: 4.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Powder for inhalation: ~3 hours (after a single 112 mg dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Powder for inhalation: 60 minutes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031308\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tobi Podhaler Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">28 mg (8): $434.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Bethkis Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/4 mL (4 mL): $121.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Kitabis Pak Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (5 mL): $96.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Tobi Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (5 mL): $157.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Tobramycin Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (5 mL): $128.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45650000\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bramitob (AT, BR, CH, CO, CZ, DE, ES, GB, GR, HR, HU, IE, IL, IT, LT, LV, MT, NL, PL, PT, RU, SK);</li>\n      <li>Bridul (AR);</li>\n      <li>Gemebcin (DE);</li>\n      <li>Nebris (CZ);</li>\n      <li>Tobi (AR, AT, AU, BD, BE, BG, BR, CH, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HN, HU, IE, IL, IT, JP, LB, LV, MT, MX, NI, NL, NO, NZ, PA, PE, PL, PT, PY, QA, RO, RU, SE, SK, SV, TR, TW);</li>\n      <li>Tobi Podhaler (AU, CO, CZ, FR, GB, HR, IL, IS, LT, LU, MT, NO, PT, SA, SI, SK, TR);</li>\n      <li>Tobradosa (EC);</li>\n      <li>Tobramist (IN);</li>\n      <li>Zoteon (CL);</li>\n      <li>Zoteon Podhaler (CL, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdulhamid I, Wise TL, Andrews S, et al, &quot;Elevated Serum Tobramycin Concentrations After Treatment With Tobramycin Inhalation in a Preterm Infant,&quot; <i>Pharmacotherapy</i>, 2008, 28(7):939-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/18576909/pubmed\" target=\"_blank\" id=\"18576909\">18576909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bethkis solution (tobramycin) [prescribing information]. Woodstock, IL: Catalent Pharma Solutions LLC; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourget P, Fernandez H, Delouis C, et al, &quot;Pharmacokinetics of Tobramycin in Pregnant Women. Safety and Efficacy of a Once-Daily Dose Regimen,&quot; <i>J Clin Pharm Ther</i>, 1991, 16(3):167-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/1869596/pubmed\" target=\"_blank\" id=\"1869596\">1869596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edenborough FP, Borgo G, Knoop C, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. <i>J Cyst Fibros</i>. 2008;7(Suppl 1):S2-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/18024241 /pubmed\" target=\"_blank\" id=\"18024241 \">18024241 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitabis Pak inhalation solution (tobramycin) [prescribing information]. Woodstock, IL: Catalent Pharma Solutions, LLC; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Festini F, Ciuti R, Taccetti G, et al, &quot;Breast-Feeding in a Woman With Cystic Fibrosis Undergoing Antibiotic Intravenous Treatment,&quot; <i>J Matern Fetal Neonatal Med</i>, 2006, 19(6):375-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/16801316/pubmed\" target=\"_blank\" id=\"16801316\">16801316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <b></b> MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. <i>Pediatr Pulmonol</i>. 1989;7(1):42-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/2505216/pubmed\" target=\"_blank\" id=\"2505216\">2505216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramsey BW, Pepe MS, Quan JM, et al, &quot;Intermittent Administration of Inhaled Tobramycin in Patients With Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group,&quot; <i>N Engl J Med</i>, 1999, 340(1):23-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/9878641/pubmed\" target=\"_blank\" id=\"9878641\">9878641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Redmann S, Wainwright C, Stacey S, et al, &quot;Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI): A Short Report,&quot; <i>Ther Drug Monit</i>, 2005, 27(2):205-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/15795653/pubmed\" target=\"_blank\" id=\"15795653\">15795653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. <i>J Aerosol Med Pulm Drug Deliv</i>. 2008;21(1):71-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/18518833/pubmed\" target=\"_blank\" id=\"18518833\">18518833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaw PK, Braun TL, Liebergen A, et al, &quot;Aerosolized Tobramycin Pharmacokinetics in Cystic Fibrosis Patients,&quot; <i>J Pediatr Pharm Pract</i>, 1997, 2(1):23-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steinkamp G, T&uuml;mmler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. <i>Pediatr Pulmonol</i>. 1989;6(2):91-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/2494640/pubmed\" target=\"_blank\" id=\"2494640\">2494640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobi Podhaler capsule (tobramycin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uwaydah M, Bibi S, and Salman S, &quot;Therapeutic Efficacy of Tobramycin - A Clinical and Laboratory Evaluation,&quot; <i>J Antimicrob Chemother</i>, 1975, 1(4):429-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-pediatric-drug-information/abstract-text/1107297/pubmed\" target=\"_blank\" id=\"1107297\">1107297</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105136 Version 32.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45031230\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45031231\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F45503733\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F45503737\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45031304\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F45031233\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45503738\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F45031263\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45503734\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45031224\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45031253\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45031248\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45031249\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F45504057\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45031258\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45031255\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F45031244\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45031245\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45503739\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F45503740\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45031267\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F45031270\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45031308\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45650000\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/105136|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tobramycin-oral-inhalation-drug-information\" class=\"drug drug_general\">Tobramycin (oral inhalation): Drug information \t</a></li><li><a href=\"topic.htm?path=tobramycin-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Tobramycin (oral inhalation): Patient drug information \t</a></li></ul></div></div>","javascript":null}